Humanigen (formerly known as KaloBios) is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. The Company's focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Its lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment.
Type | Public | |
Founded | 2000 | |
HQ | Burlingame, CA, US | Map |
Website | humanigen.com |
USD | |
---|---|
Revenue (FY, 2020) | 312.0k |
Net income (FY, 2020) | (89.5m) |
EBIT (FY, 2020) | (88.2m) |
Market capitalization (30-Mar-2021) | 1.2b |
Closing stock price (30-Mar-2021) | 21.7 |
Cash (31-Dec-2020) | 67.7m |
USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.2m | 2.5m | 2.5m | 2.4m | 1.5m | 2.0m | 4.0m | 2.0m | 1.8m | 1.9m | 1.7m | 1.5m | 1.4m | 2.0m |
R&D expense | 1.7m | 4.4m | 1.7m | 2.7m | 3.9m | 3.8m | 696.0k | 577.0k | 535.0k | 359.0k | 1.2m | 549.0k | 659.0k | 21.1m |
Operating expense total | 2.9m | 6.9m | 4.2m | 5.1m | 5.4m | 5.8m | 4.7m | 2.6m | 2.3m | 2.2m | 3.0m | 2.0m | 2.1m | 23.1m |
EBIT | (2.9m) | (6.9m) | (4.2m) | (5.1m) | (5.4m) | (5.8m) | (4.7m) | (2.6m) | (2.3m) | (2.2m) | (3.0m) | (2.0m) | (2.1m) | (23.1m) |
USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.6m | 11.9m | 2.9m | 4.0m | 103.0k | 1.1m | 1.6m | 267.0k | 2.0m | 180.0k | 1.1m | 157.0k | 68.0k | 41.7m |
Prepaid Expenses | 1.7m | 1.3m | 1.8m | 1.7m | 1.5m | 1.2m | 838.0k | 665.0k | 504.0k | 479.0k | 425.0k | 366.0k | 293.0k | 770.0k |
Current Assets | 8.3m | 13.3m | 4.7m | 5.7m | 1.7m | 2.3m | 2.4m | 932.0k | 2.5m | 659.0k | 1.5m | 523.0k | 361.0k | 42.5m |
PP&E | 170.0k | 145.0k | 121.0k | 53.0k | 41.0k | 30.0k | 10.0k |
USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (5.4m) | (17.4m) | (22.0m) | (5.5m) | (11.7m) | (18.9m) | (5.1m) | (7.8m) | (9.9m) | (2.5m) | (5.9m) | (8.3m) | (2.5m) | (26.5m) |
Depreciation and Amortization | 33.0k | 58.0k | 81.0k | 14.0k | 27.0k | 38.0k | 10.0k | 19.0k | 19.0k | |||||
Accounts Payable | 3.2m | 4.6m | 3.5m | (507.0k) | (434.0k) | 327.0k | (28.0k) | (88.0k) | (159.0k) | 592.0k | 717.0k | 1.1m | 860.0k | (2.9m) |
Cash From Operating Activities | (2.0m) | (9.0m) | (17.9m) | (4.4m) | (8.3m) | (12.3m) | (1.8m) | (3.7m) | (5.0m) | (684.0k) | (2.3m) | (3.5m) | (607.0k) | (22.6m) |
USD | FY, 2015 |
---|---|
Financial Leverage | 1.9 x |
Company Name | Date | Deal Size |
---|---|---|
Celscia Therapeutics | ||
KaloBios |
When was Humanigen founded?
Humanigen was founded in 2000.
Who are Humanigen key executives?
Humanigen's key executives are Cameron Durrant, Bob Atwill and Dale Chappell.
How many employees does Humanigen have?
Humanigen has 2 employees.
What is Humanigen revenue?
Latest Humanigen annual revenue is $312 k.
What is Humanigen revenue per employee?
Latest Humanigen revenue per employee is $156 k.
Who are Humanigen competitors?
Competitors of Humanigen include Abcam, XOMA and MiracleCord.
Where is Humanigen headquarters?
Humanigen headquarters is located at 533 Airport Blvd #400, Burlingame.
Where are Humanigen offices?
Humanigen has offices in Burlingame and Kansas City.
How many offices does Humanigen have?
Humanigen has 2 offices.
Receive alerts for 300+ data fields across thousands of companies